Quick Answer
PMV Pharmaceuticals, Inc. reported Operating Income of -$86.21 million for fiscal year 2025.
PMV Pharmaceuticals, Inc. Operating Income — Annual History
| Fiscal Year | Operating Income | YoY Change |
|---|---|---|
| 2025 | -$86.21M | -0.9% |
| 2024 | -$85.45M | -6.6% |
| 2023 | -$80.13M | -4.0% |
| 2022 | -$77.04M | -32.2% |
| 2021 | -$58.29M | -66.8% |
| 2020 | -$34.94M | -31.2% |
| 2019 | -$26.64M | -41.0% |
| 2018 | -$18.89M | — |
Quarterly Operating Income
| Quarter Ending | Operating Income | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$22.52M | -2.9% | +1.6% |
| June 30, 2025 | -$22.88M | -13.4% | -6.1% |
| March 31, 2025 | -$21.56M | -18.3% | +1.5% |
| September 30, 2024 | -$21.89M | -11.5% | -8.5% |
| June 30, 2024 | -$20.17M | -0.2% | -10.7% |
| March 31, 2024 | -$18.22M | +15.2% | +7.2% |
| September 30, 2023 | -$19.63M | -1.3% | +2.5% |
| June 30, 2023 | -$20.12M | -12.5% | +6.3% |
- PMV Pharmaceuticals, Inc. showed a decrease of -0.9% in Operating Income compared to the prior fiscal year.
- Over the 2018–2025 period, PMV Pharmaceuticals, Inc.’s operating income has declined by 356.3% (from -$18.89 million to -$86.21 million).
- The most recent figure is from PMV Pharmaceuticals, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 6, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: